Arcutis Biotherapeutics, INC Form 4 insider transactions

Arcutis Biotherapeutics CEO Todd Watanabe sold 45,000 shares of common stock for approximately $884,574 in pre-planned transactions.

Arcutis Biotherapeutics Director Howard G. Welgus exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 trading plan.

Arcutis Biotherapeutics CEO Todd Watanabe sold over 10,000 shares of common stock in early September 2025, executed under a pre-arranged 10b5-1 trading plan.

Arcutis Biotherapeutics' SVP General Counsel Masaru Matsuda sold 36,130 shares of common stock for a weighted average price of $16.156 per share.

Arcutis Biotherapeutics Director Howard G. Welgus sold 10,000 shares of common stock for $15.6383 per share, following an option exercise, as part of a pre-arranged 10b5-1 trading plan.

Arcutis Biotherapeutics' Executive Vice President and Chief Medical Officer, Patrick Burnett, sold 4,188 shares of common stock in August 2025 to cover tax withholding obligations related to vested restricted stock units.

Arcutis Biotherapeutics' Executive Vice President and Chief Medical Officer, Patrick Burnett, sold 3,847 shares of common stock for approximately $14.03 per share under a pre-arranged trading plan.

Arcutis Biotherapeutics CEO Todd Watanabe sold 11,547 shares of common stock to cover tax withholding obligations related to RSU vesting.

Arcutis Biotherapeutics' Executive Vice President and Chief Medical Officer, Patrick Burnett, sold 2,622 shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.

Arcutis Biotherapeutics' SVP Chief Financial Officer, Latha Vairavan, sold 89 shares of common stock to cover tax withholding obligations related to RSU vesting.

Arcutis Biotherapeutics' SVP General Counsel sold 6,330 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Arcutis Biotherapeutics Director Howard G. Welgus sold 10,000 shares of common stock for approximately $142,982 through a pre-arranged 10b5-1 trading plan.

Patrick Burnett, Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, Inc., sold common stock totaling 28,750 shares in July 2025, pursuant to a pre-arranged 10b5-1 trading plan.

Arcutis Biotherapeutics Director Howard G. Welgus sold 9,208 shares of common stock for a weighted average price of $13.8391 per share on July 1, 2025, pursuant to a Rule 10b5-1 trading plan.

Howard G. Welgus, a Director at Arcutis Biotherapeutics, Inc., sold 10,139 shares of common stock for approximately $135,560 under a pre-arranged 10b5-1 trading plan.

Arcutis Biotherapeutics, Inc. Director Patrick J. Heron reported the acquisition of 2,646 shares of common stock at a weighted average price of $13.0803 per share, signaling increased insider confidence.

Arcutis Biotherapeutics, Inc. Director Sue-Jean Lin reported the acquisition of 7,609 Restricted Stock Units and 20,568 stock options as part of her compensation for service.

Arcutis Biotherapeutics, Inc. Director Howard G. Welgus was granted 7,609 restricted stock units and 20,568 stock options as part of his compensation for service.

Patrick J. Heron, a Director and 10% owner of Arcutis Biotherapeutics, Inc., reported the acquisition of Restricted Stock Units and stock options as part of his compensation.

Arcutis Biotherapeutics, Inc. Director Keith R. Leonard reported the acquisition of 7,609 Restricted Stock Units and 20,568 stock options as part of his compensation for service.

Arcutis Biotherapeutics, Inc. Director Terrie Curran reported the acquisition of 7,609 Restricted Stock Units and 20,568 stock options with an exercise price of $13.5, granted for her service.

Neha Krishnamohan, a Director at Arcutis Biotherapeutics, Inc., reported the acquisition of 7,609 Restricted Stock Units and 20,568 stock options as part of her compensation for service.

Arcutis Biotherapeutics, Inc. Director Halley E. Gilbert was granted 7,609 Restricted Stock Units and options to purchase 20,568 shares of common stock, with vesting tied to continued service.

Arcutis Biotherapeutics, Inc. Director Bhaskar Chaudhuri reported the acquisition of 7,609 Restricted Stock Units and 20,568 stock options as compensation for his service, with vesting tied to continued service.

Arcutis Biotherapeutics President and CEO, Todd Franklin Watanabe, reported multiple gift-related transactions of common stock on June 10, 2025, reallocating shares from direct to indirect beneficial ownership via trusts.

Patrick J. Heron, a Director at Arcutis Biotherapeutics, Inc., has increased his beneficial ownership in the company through recent stock purchases totaling 2,268 shares.

Masaru Matsuda, SVP General Counsel and Corporate Secretary of Arcutis Biotherapeutics, Inc., sold 1,800 shares of common stock to satisfy tax withholding obligations related to vested performance stock units.

Patrick J. Heron, a Director at Arcutis Biotherapeutics, Inc., has increased his beneficial ownership in the company by acquiring 5,040 shares of common stock through recent transactions.

Larry Todd Edwards, EVP Chief Commercial Officer at Arcutis Biotherapeutics, sold shares to cover tax withholding obligations related to vesting Restricted Stock Units.

Director Patrick J. Heron reports purchasing 2,520 shares of Arcutis Biotherapeutics at an average price of $13.6178.